DDInter458 DDInter1000
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults. It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma and relapsed or refractory myelodysplastic syndromes in adults. The drug is only effective in patients with a susceptible IDH1 mutation. In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of ivosidenib and recommended it be granted marketing authorization for the treatment of acute myeloid leukemia and cholangiocarcinoma. It was fully approved by the EMA in May 2023.
Cyclosporine {u} (Compound) binds {v} (Gene) SLCO1A2
SLCO1A2 {u} (Gene) is bound by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivosidenib
Cyclosporine {u} (Compound) binds {v} (Gene) SLCO1A2
SLCO1A2 {u} (Gene) is bound by {v} (Compound) Atorvastatin
Atorvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivosidenib
Cyclosporine {u} (Compound) causes {v} (Side Effect) Urticaria
Urticaria {u} (Side Effect) is caused by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivosidenib
Cyclosporine {u} (Compound) binds {v} (Gene) SLCO1A2
SLCO1A2 {u} (Gene) is bound by {v} (Compound) Nelfinavir
Nelfinavir {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Cyclosporine {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Nicardipine
Nicardipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivosidenib
Cyclosporine {u} (Compound) causes {v} (Side Effect) Vascular purpura
Vascular purpura {u} (Side Effect) is caused by {v} (Compound) Venlafaxine
Venlafaxine {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Cyclosporine {u} (Compound) upregulates {v} (Gene) EPRS
EPRS {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivosidenib
Cyclosporine {u} (Compound) downregulates {v} (Gene) HSPA8
HSPA8 {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivosidenib
Cyclosporine {u} (Compound) upregulates {v} (Gene) EPRS
EPRS {u} (Gene) is downregulated by {v} (Compound) Bisacodyl
Bisacodyl {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivosidenib
Cyclosporine {u} (Compound) downregulates {v} (Gene) HSPA8
HSPA8 {u} (Gene) is downregulated by {v} (Compound) Bisacodyl
Bisacodyl {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivosidenib
Cyclosporine (Compound) binds SLCO1A2 (Gene) and SLCO1A2 (Gene) is bound by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Cyclosporine (Compound) binds SLCO1A2 (Gene) and SLCO1A2 (Gene) is bound by Atorvastatin (Compound) and Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Cyclosporine (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Cyclosporine (Compound) binds SLCO1A2 (Gene) and SLCO1A2 (Gene) is bound by Nelfinavir (Compound) and Nelfinavir may lead to a major life threatening interaction when taken with Ivosidenib
Cyclosporine (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Cyclosporine (Compound) causes Vascular purpura (Side Effect) and Vascular purpura (Side Effect) is caused by Venlafaxine (Compound) and Venlafaxine may lead to a major life threatening interaction when taken with Ivosidenib
Cyclosporine (Compound) upregulates EPRS (Gene) and EPRS (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Cyclosporine (Compound) downregulates HSPA8 (Gene) and HSPA8 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Cyclosporine (Compound) upregulates EPRS (Gene) and EPRS (Gene) is downregulated by Bisacodyl (Compound) and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Cyclosporine (Compound) downregulates HSPA8 (Gene) and HSPA8 (Gene) is downregulated by Bisacodyl (Compound) and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib